ResearcherJohns Hopkins UniversityActive in the last 2 years
Jun-Ke Wang
Matched on ORCID iD 0000-0002-8605-3087; OpenAlex author ID A5100772954. Sources: OpenAlex.
Their work
- Papers
- 3
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 26
2022: 1 paper · 2023: none · 2024: 1 paper · 2025: 1 paper
Papers 3
- Chemotherapy in synergy with innate immune agonists enhances T cell priming for checkpoint inhibitor treatment in pancreatic cancer. Co-author DOI 10.1186/s40364-024-00721-7↗
- Neoadjuvant radioimmunotherapy in pancreatic cancer enhances effector T cell infiltration and shortens their distances to tumor cells. Co-author DOI 10.1126/sciadv.adk1827↗
- CCR2/CCR5 inhibitor permits the radiation-induced effector T cell infiltration in pancreatic adenocarcinoma. Co-author DOI 10.1084/jem.20211631↗
Closest collaborators
The 25 strongest of 26 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Nan Niu · 3 shared papers, 2022–2025 · strength 0.48
- Paper Chemotherapy in synergy with innate immune agonists enhances T cell priming for checkpoint inhibitor treatment in pancr… DOI 10.1186/s40364-024-00721-7↗
- Paper Neoadjuvant radioimmunotherapy in pancreatic cancer enhances effector T cell infiltration and shortens their distances … DOI 10.1126/sciadv.adk1827↗
- Paper CCR2/CCR5 inhibitor permits the radiation-induced effector T cell infiltration in pancreatic adenocarcinoma. DOI 10.1084/jem.20211631↗
- Keyu Li · 3 shared papers, 2022–2025 · strength 0.48
- Paper Chemotherapy in synergy with innate immune agonists enhances T cell priming for checkpoint inhibitor treatment in pancr… DOI 10.1186/s40364-024-00721-7↗
- Paper Neoadjuvant radioimmunotherapy in pancreatic cancer enhances effector T cell infiltration and shortens their distances … DOI 10.1126/sciadv.adk1827↗
- Paper CCR2/CCR5 inhibitor permits the radiation-induced effector T cell infiltration in pancreatic adenocarcinoma. DOI 10.1084/jem.20211631↗
- Lei Zheng · 3 shared papers, 2022–2025 · strength 0.48
- Paper Chemotherapy in synergy with innate immune agonists enhances T cell priming for checkpoint inhibitor treatment in pancr… DOI 10.1186/s40364-024-00721-7↗
- Paper Neoadjuvant radioimmunotherapy in pancreatic cancer enhances effector T cell infiltration and shortens their distances … DOI 10.1126/sciadv.adk1827↗
- Paper CCR2/CCR5 inhibitor permits the radiation-induced effector T cell infiltration in pancreatic adenocarcinoma. DOI 10.1084/jem.20211631↗
- Brian T. Herbst · 2 shared papers, 2022–2025 · strength 0.33
- Jin Peng He · 2 shared papers, 2022–2024 · strength 0.27
- Amol Kumar Narang · 2 shared papers, 2022–2024 · strength 0.27
- Mengni He · 1 shared paper, 2025 · strength 0.21
- Sami Shoucair · 1 shared paper, 2025 · strength 0.21
- Yiping Mou · 1 shared paper, 2025 · strength 0.21
- Robert A. Anders · 1 shared paper, 2024 · strength 0.16
- Valerie Lee · 1 shared paper, 2024 · strength 0.16
- Joseph M. Herman · 1 shared paper, 2024 · strength 0.16
- Tao Xia · 1 shared paper, 2024 · strength 0.16
- Tengyi Zhang · 1 shared paper, 2024 · strength 0.16
- Elizabeth M. Jaffee · 1 shared paper, 2024 · strength 0.16
- Arsen Osipov · 1 shared paper, 2024 · strength 0.16
- Hao Wang · 1 shared paper, 2024 · strength 0.16
- Daniel A. Laheru · 1 shared paper, 2024 · strength 0.16
- Ding Ding · 1 shared paper, 2022 · strength 0.12
- Kenji Fujiwara · 1 shared paper, 2022 · strength 0.12
- Sophia Y. Chen · 1 shared paper, 2022 · strength 0.12
- Stephen T. Muth · 1 shared paper, 2022 · strength 0.12
- May Tun Saung · 1 shared paper, 2022 · strength 0.12
- Jianxin Wang · 1 shared paper, 2022 · strength 0.12
- Noah S Rozich · 1 shared paper, 2022 · strength 0.12
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.